Rhumbline Advisers Uni Qure N.V. Transaction History

Rhumbline Advisers

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	SELL	$11.12 - $22.2 $6,449 - $12,876	-580 Reduced 1.54%	36,987 $423,000
Q1 2023 May 11, 2023	BUY	$18.7 - $23.07 $99,970 - $123,332	5,346 Added 16.59%	37,567 $757,000
Q4 2022 Feb 14, 2023	SELL	$18.12 - $27.32 $20,566 - $31,008	-1,135 Reduced 3.4%	32,221 $730,000
Q3 2022 Nov 10, 2022	BUY	$16.98 - $25.54 $71,366 - $107,344	4,203 Added 14.42%	33,356 $626,000
Q2 2022 Aug 11, 2022	SELL	$13.15 - $20.45 $9,297 - $14,458	-707 Reduced 2.37%	29,153 $543,000
Q1 2022 May 12, 2022	BUY	$14.54 - $21.5 $69,486 - $102,748	4,779 Added 19.05%	29,860 $540,000
Q4 2021 Feb 10, 2022	SELL	$20.24 - $36.01 $60,983 - $108,498	-3,013 Reduced 10.72%	25,081 $520,000
Q3 2021 Nov 12, 2021	BUY	$26.01 - $38.22 $730,724 - $1.07 Million	28,094 New	28,094 $899,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.